公开(公告)号：US11952344B2

公开(公告)日：2024-04-09

申请号：US17754118

申请日：2020-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya Oguro ,  Makoto Kamata ,  Shuhei Ikeda ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Shigemitsu Matsumoto ,  Hirotaka Kamitani ,  Takaharu Hirayama ,  Toshio Tanaka ,  Hiroshi Banno ,  Nobuyuki Takakura ,  Jinichi Yonemori ,  Takuya Fujimoto

IPC: C07D213/61 ,  A61K31/444 ,  A61K31/495 ,  A61P25/00 ,  A61P29/00 ,  C07D211/04 ,  C07D213/65 ,  C07D213/68 ,  C07D221/04 ,  C07D237/08 ,  C07D239/26 ,  C07D239/34 ,  C07D333/38 ,  C07D401/12 ,  C07D405/02

CPC classification number: C07D211/04 ,  C07D237/08 ,  C07D239/26 ,  C07D405/02

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

公开(公告)号：US11827601B2

公开(公告)日：2023-11-28

申请号：US18087302

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei Ikeda ,  Makoto Kamata ,  Yuya Oguro

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

CPC classification number: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US11242348B2

公开(公告)日：2022-02-08

申请号：US16651840

申请日：2018-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Makoto Kamata ,  Hideyuki Sugiyama ,  Minoru Nakamura ,  Masataka Murakami ,  Shuhei Ikeda ,  Tomohiro Okawa ,  Hidekazu Tokuhara

IPC: C07D487/10 ,  A61P25/28 ,  A61K9/20 ,  A61K9/48

Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US10112956B2

公开(公告)日：2018-10-30

申请号：US15467548

申请日：2017-03-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Yuichi Kajita ,  Masato Yoshikawa ,  Shuhei Ikeda ,  Eiji Kimura ,  Tomoaki Hasui ,  Toshiya Nishi ,  Hiromi Fukuda

IPC: C07D498/08 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D471/10 ,  C07D405/14 ,  C07D213/74 ,  C07D239/42 ,  C07D401/04 ,  C07D401/14 ,  C07D487/18 ,  C07D401/12 ,  C07D413/04 ,  C07D417/04 ,  C07D451/02 ,  C07D451/04 ,  C07D487/10 ,  C07D491/18 ,  C07D403/12 ,  C07D491/08 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D213/12 ,  A61K9/20 ,  A61K9/48 ,  C07D213/72 ,  C07D487/08 ,  C12N9/99

Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20170283406A1

公开(公告)日：2017-10-05

申请号：US15474192

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei Ikeda ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: C07D413/14 ,  C07D413/08 ,  C07D405/14 ,  C07D401/08

CPC classification number: C07D413/14 ,  C07D401/06 ,  C07D401/08 ,  C07D405/14 ,  C07D413/06 ,  C07D413/08

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.